Stroke/Systemic Embolism and Major Bleeding in Patients Newly Treated With Oral Anticoagulants: a Real World Study From Portuguese Administrative Claims Data

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists (Primary)
Indications Embolism; Haemorrhage; Stroke
Focus Therapeutic Use
Sponsors Pfizer

04 Apr 2023 Eligibility criteria amended to include subjects 18 years and above.
08 Apr 2022 Planned End Date changed from 1 Jan 2022 to 1 Dec 2020.
08 Apr 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com